Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide

MLA

Alessia Lodi, et al. “Circulating Metabolites Associated with Tumor Hypoxia and Early Response to Treatment in Bevacizumab-Refractory Glioblastoma after Combined Bevacizumab and Evofosfamide.” Frontiers in Oncology, vol. 12, Sept. 2022. EBSCOhost, https://doi.org/10.3389/fonc.2022.900082.

APA

Alessia Lodi, Renu Pandey, Jennifer Chiou, Ayon Bhattacharya, Shiliang Huang, Xingxin Pan, Brandon Burgman, S. Stephen Yi, Stefano Tiziani, & Andrew J. Brenner. (2022). Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.900082

Chicago

Alessia Lodi, Renu Pandey, Jennifer Chiou, Ayon Bhattacharya, Shiliang Huang, Xingxin Pan, Brandon Burgman, S. Stephen Yi, Stefano Tiziani, and Andrew J. Brenner. 2022. “Circulating Metabolites Associated with Tumor Hypoxia and Early Response to Treatment in Bevacizumab-Refractory Glioblastoma after Combined Bevacizumab and Evofosfamide.” Frontiers in Oncology 12 (September). doi:10.3389/fonc.2022.900082.